Comparison of pramipexole and citalopram in the treatment of depression in Parkinson's disease: A randomized parallel-group trial.

In both the citalopram and pramipexole groups, the BDI score showed a highly significant decrease with a large effect size ( r ≥ 0.6) analyzed by a Wilcoxon signed-rank test ( Z = −4.018, P < 0.0001, and r = −0.877 for citalopram group and Z = −3.926, P < 0.0001, and r = −0.878 for pramipexole group).

also in 132,142 other papers